No Data
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Anhui Huaheng Biotechnology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Anhui Huaheng Biotechnology Co., Ltd.
Weak expansion of sales channels? Leading synthetic biology company Huaheng Biological's net profit fell more than 20% in the first half of the year.
Due to increased competition and rising costs, Huaheng Biotech's net income for the first half of the year fell by 21.72%. It is stated that the sales channels for the core product L-Xeonine need to be further expanded, and market share needs to be increased. The registered and effective issuance plan of Huaheng Biotech has been registered and effective, but it is stated that if the project cannot generate benefits as expected or the actual income is lower than expected, there may be a risk of reduced profitability.
Huaheng Bio (688639.SH): The net income in the first half of the year was 0.15 billion yuan, a year-on-year decrease of 21.72%.
On August 27, Guolonghui announced its semi-annual report for 2024. During the reporting period, the company achieved revenue of 1.016 billion yuan, a year-on-year increase of 19.57%; net income attributable to shareholders of the listed company was 0.15 billion yuan, a year-on-year decrease of 21.72%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.148 billion yuan, a year-on-year decrease of 22.14%; basic earnings per share was 0.95 yuan.
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
No Data
No Data